Preferences help
enabled [disable] Abstract
Number of results
2013 | 60 | 3 | 299-305
Article title

Kinin-generating cellular model obtained from human glioblastoma cell line U-373

Title variants
Languages of publication
Kinins, a group of important pro-inflammatory peptides, are abundantly found in tissues and biological fluids of cancer patients. Bradykinin, the major representative of kinins, induces vascular permeability and, in consequence, promotes tumor expansion. Additionally, the kinin-induced inflammatory responses, especially those mediated by kinin metabolites without the C-terminal arginine residue, lead to enhanced tumor growth. The present study aimed at analyzing the ability of the human glioblastoma cell line U-373, derived from a malignant tumor, to produce kinin peptides. The proteins involved in kinin generation, i.e., the kininogens and the kallikreins, were shown to be expressed in these cells. Moreover, tumor necrosis factor α, a proinflammatory cytokine that mediates tumorigenesis, was found to enhance the expression of enzymes associated with kinin production. The strong binding of kininogen to the cell surface and the enzymatic degradation of this protein by cells suggest the activation of kinin-generating systems. Indeed, glioblastoma cells, pre-treated with tumor necrosis factor α, released kinin peptides from exogenous kininogen. The expression of kinin receptors in these cells was also shown to increase under the influence of this cytokine. Our results suggest that the human glioblastoma cell line U-373 constitutes a good cellular model that can be helpful in cancer research focused on kinin-induced inflammation. Furthermore, our findings can contribute to new approaches in cancer treatment with the use of kinin receptor antagonists and inhibitors of kinin production.
Physical description
  • Barbasz A, Kozik A (2009) The assembly and activation of the kinin-forming systems on the surface of human U-937 macrophage-like cells. Biol Chem 390: 269-275.
  • Bhoola KD, Figueroa CD, Worthy K (1992) Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol Rev 44: 1-80.
  • Blais C, Marceau F, Rouleau JL, Adam A (2000) The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides 21: 1903-1940.
  • Borgoño CA, Michael IP, Diamandis EP (2004) Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2: 257-280.
  • Chee J, Naran A, Misso NL, Thompson PJ, Bhoola KD (2008) Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol Chem 389: 1225-1233.
  • Colman RW, Schmaier AH (1997) Contact system. A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90: 3819-3843.
  • Dean RL, Emerich DF, Hasler BP, Bartus RT (1999) Cereport® (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro Oncol 1: 268-274.
  • Fernando L, Natesan S, Joseph K, Kaplan AP (2003) High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thromb Haemost 90: 787-795.
  • Figueroa CD, Ehrenfeld P, Bhoola KD (2012) Kinin receptors as targets for cancer therapy. Expert Opin Ther Targets 16: 299-312.
  • Finger EC, Giaccia JA (2010) Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 29 285-293.
  • Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta 1796: 293-308.
  • Guevara-Lora I, Labedz A, Skrzeczynska-Moncznik J, Kozik A (2011) Bradykinin and des-Arg10-kallidin enhance the adhesion of polymorphonuclear leukocytes to extracellular matrix proteins and endothelial cells. Cell Commun Adhes 18: 67-71.
  • Guevara-Lora I, Majkucinska M, Barbasz A, Faussner A, Kozik A (2011) Kinin generation from exogenous kininogens at the surface of retinoic acid-differentiated human neuroblastoma IMR-32 cells after stimulation with interferon-γ. Peptides 32: 1193-1200.
  • Joseph K, Kaplan AP (2005) Formation of bradykinin: a major contribution to the innate inflammatory response. Adv Immunol 86: 159-208.
  • Jutras S, Bachvarova M, Keita M, Bascands JL, Mes-Masson AM, Stewart JM, Gera L, Bachvarov D (2010) Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells - analysis of the molecular mechanisms of its antiproliferative action. FEBS J 277: 5146-5160.
  • Lee H-W, Choi H-J, Ha S-J, Lee K-T, Kwon Y-G (2013) Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim Biophys Acta 1835: 170-179.
  • Leeb-Lundberg LMF, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanism to pathophysiological consequences. Pharmacol Rev 57: 27-77.
  • Liu L, Xue Y, Liu Y (2010) Bradykinin increases the permeability of the blood-tumor barrier by the caveolae-mediated transcellular pathway. J Neurooncol 99: 187-194.
  • López-Valdés HE, Beltran-Parraza L, Brennan KC, Charles AC (2010) Bradykinin increases resensitization of purinergic receptor signaling in glioma cells. Cancer Cell Int 10: 35-43.
  • Lu D-Y, Leung Y-M, Huang S-M, Wong K-L (2010) Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. J Cell Biochem 110: 141-150.
  • Lynch DR, Braas KM, Hutton JC, Snyder SH (1990) Carboxypeptidase E (CPE): immunocytochemical localization in the rat central nervous system and pituitary gland. J Neurosc 10: 1592-l 599.
  • Maeda H, Wu J, Okamoto T, Maruo K, Akaike T (1999) Kallikrein-kinin in infection and cancer. Immunopharmacology 43: 115-128.
  • McLean PG, Ahluwalia A, Perretti M (2000) Association between kinin B1 receptor expression and leukocyte trafficking across mouse mesenteric postcapillary venules. J Exp Med 192: 367-380.
  • Molina L, Matus CE, Astroza A., Pavicic F, Tapia E, Toledo C, Perez J, Nualart F, Gonzalez CB, Burgos R, Figueroa CD, Ehrenfeld P, Poblete MT (2009) Stimulation of the bradykinin B1 receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK1/2 signaling pathway. Breast Cancer Res Treat 118: 499-510.
  • Montana V, Sontheimer H (2011) Bradykinin promotes the chemo-tactic invasion of primary brain tumors. J Neurosci 31: 4858-4867.
  • Murthy SRK, Pacak K, Loh YP (2010) Carboxypeptidase E: Elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers. Cell Mol Neurobiol 30: 1377-1381.
  • Nagae A, Deddish PA, Becker RP, Anderson CH, Abe M, Tan F, Skidgel RA, Erdös EG (1992) Carboxypeptidase M in brain and peripheral nerves. J Neurochem 59: 2201-2212.
  • Obiezu CV, Diamandis EP (2005) Human tissue kallikrein gene family: applications in cancer. Cancer Letters 224: 1-22.
  • Scicli AG, Forbes G, Nolly H, Dujovny M, Carretero OA (1984) Kallikrein-kinins in the central nervous system. Clin Exp Hypertens A 6: 1731-1738.
  • Sharma JN, Al-Sherif GJ (2011) The Kinin System: Present and future pharmacological targets. Am J Biomed Sci 3: 156-169.
  • Tan F, Deddish P A, Skidgel RA (1992) Human carboxypeptidase M. Methods Enzymol 248: 663-675.
  • Toledo C, Matus CE, Barraza X, Arroyo P, Ehrenfeld P, Figueroa CD, Bhoola KD, del Pozo M, Poblete MT (2012) Expression of HER2 and bradykinin B1 receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol 18: 1208-1215.
  • Tysnes BB, Mahesparan R (2001) Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol 53: 129-147.
  • Varano Della Vergiliana JF, Lansley S, Tan AL, Creaney J, Lee YC, Stewart GA (2011) Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation. Biol Chem 392: 633-642.
  • Wu J, Akaike T, Hayashida K, Miyamoto Y, Nakagawa T, Miyakawa K, Muller-Esterl W, Maeda H (2002) Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 98: 29-35.
  • Zubakova R, Gille A, Faussner A, Hilgenfeldt U (2007) Ca2+ signalling of kinins in cells expressing rat, mouse and human B1/B2-receptor. Int Immunopharmacol 8: 276-281.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.